Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 73–96 of 245
WELL Health owned Wisp launches longevity care suite
Wisp, a telehealth platform owned by WELL Health, launched a longevity care suite offering glutathione, NAD+, and low-dose naltrexone to support cellular energy, immune function, and biological repair in women. The initiative addresses gaps in aging care during perimenopause and menopause through clinician-guided, asynchronous consultations and personalized treatment adjustments.
Madrid's Longevity Summit: Translating 85+ Years Into Clinical Practice
The International Longevity Summit Madrid 2026 will convene leading scientists, physicians, and entrepreneurs in September–October 2026 at Spain's Royal National Academy of Medicine to advance research and clinical application of human lifespan extension. Madrid's position as Europe's longest-living region makes it an institutional hub for translating longevity science into population health outcomes.
Human Evidence Over Promise: Longevity Awards Redefine Success
The TOP 10 Longevity Breakthrough Awards 2026 establish a credibility filter for longevity interventions by requiring human clinical data and a realistic two-year pathway to implementation—not just mechanistic promise. This shift reflects a field-wide recognition that the gap between laboratory evidence and clinical utility determines whether discoveries actually reach patients.
Longevity public stocks are investable: here’s a DLT Chatbot guide
This article describes a data-driven approach to constructing longevity biotech investment portfolios by mapping public companies to the hallmarks of aging rather than disease labels. The mechanism-first framework enables investors to identify companies with broader pipeline optionality and reduced concentration risk across the fragmented longevity biotech landscape.
Defeating entropy: London takes on Longevity Levels 9 and 10
A London conference examines Longevity Levels 9 and 10—strategies that shift from slowing aging to replacing worn biological structures entirely, including whole brain emulation, organ replacement, and biostasis. These approaches represent a fundamental philosophical and technical departure from maintenance-focused longevity, treating the body as a modular system where critical components can be swapped rather than repaired.
First 100 speakers revealed for The Longevity Show
The Longevity Show's inaugural speaker lineup of 100 experts signals the maturation of longevity science from academic niche to mainstream economic and cultural priority. The event's dual-track structure—pairing geroscientists with clinicians, entrepreneurs, and consumer health voices—reflects a recognition that extending healthspan requires translation from discovery into sustained behavioral change across populations.
Integrated Prevention Model Targets Healthspan at Population Scale
MORROW's Singapore flagship demonstrates an integrated model for delivering preventive healthcare at scale—combining clinical oversight with nutrition, movement, recovery, and coaching under one facility. The 45,000 sq ft installation reflects a sector-wide shift from discovering new longevity interventions toward building the infrastructure and systems required to implement them consistently and affordably.
Longevity.Technology and AND Capital Ventures launch partnership
Longevity.Technology and AND Capital Ventures announced a strategic partnership integrating AI-enabled market intelligence with operator-led investment strategy to identify growth-stage opportunities in longevity and healthspan innovation. The collaboration addresses market fragmentation by consolidating biotech, financing, clinical pipeline and public market signals into a unified intelligence platform for institutional investors.
Agentis, Ultrahuman tie wearables to Longevity Quotient
Agentis Longevity and Ultrahuman have integrated continuous glucose monitoring and wearable biomarker data into a clinical scoring system (Longevity Quotient) designed to bridge the gap between real-time metabolic data and actionable preventive care. The partnership addresses low engagement in preventive health practices by making personalized, data-driven interventions accessible at scale.
Hong Kong to host APAC longevity summit 2026
The 2026 APAC Longevity Medicine International Summit in Hong Kong will convene 2,000 researchers, clinicians, and policymakers to address the translation gap between geroscience discovery and clinical implementation. The event signals a maturation of the longevity field from laboratory breakthroughs toward systematic deployment of interventions at scale.
Biopeak’s longevity care earns repeat investor support
Biopeak, India's longevity care platform, secured $2.7 million in follow-on funding, demonstrating investor confidence in its longitudinal health optimization model. The company has progressed from concept to clinical delivery, addressing a gap in preventive care infrastructure within India's healthcare system.
Formulation Precision Over Ingredients in Longevity
Sooo.me, a bootstrapped supplement company founded by mathematician Erika Paulė, positions formulation precision and dose efficacy as central to longevity optimization rather than ingredient novelty or marketing claims. The company's approach reflects a broader shift in the longevity sector toward systems-level thinking about aging and the recognition that supplement adherence depends on integrating functional ingredients into everyday habits rather than clinical protocols.
The Longevity Investor Network Looks Back at 2025
The Longevity Investor Network deployed over $1.2 million into longevity-focused startups in 2025, continuing its mission to connect early-stage companies in aging biology, regenerative medicine, and senotherapeutics with informed capital. Since 2020, LIN has invested in 23 companies across cellular reprogramming, diagnostics, neurodegeneration, and tissue engineering, demonstrating sustained institutional commitment to translating aging science into commercial solutions.
John Hancock introduces longevity readiness tool
John Hancock has launched a personalized longevity readiness assessment tool developed with MIT AgeLab that scores individuals across eight life domains—health, finance, care, housing, daily activities, community, life transitions, and social connection. The tool addresses a critical gap in longevity planning: most interventions focus on extending lifespan rather than preparing people psychologically, socially, and practically for the reality of extended years.
TMRW lands $7m to expand longevity clinics
TMRW, an Australian longevity platform, secured $7 million in seed funding to expand clinical services and deepen biological age assessment through epigenetic testing in partnership with TruDiagnostic. The company differentiates itself by analyzing approximately 1,700 biological data points and integrating clinical support alongside diagnostics, moving beyond dashboard-only models.
Hertility announced as Women’s Health Partner for Longevity Show
Hertility has been named Scientific Lead Partner for the Women's Health Summit at the 2026 Longevity Show, positioning female biology as a structural framework—not peripheral content—for longevity science. The partnership addresses a fundamental data gap: longevity research has been calibrated to male physiology, requiring sex-specific diagnostic infrastructure and longitudinal data to advance clinical outcomes.
Cellular reprogramming enters human trials as longevity funding matures
The longevity sector has matured from speculative hype to evidence-driven investment, with capital concentration, clinical pathways, and regulatory engagement now defining the landscape. The shift from aspirational claims to measurable outcomes reflects broader maturation in biotech funding patterns and signals accelerating convergence between cellular biology research and practical medical application.
Scaling Aging Interventions: XPRIZE Judges Beyond Lab Efficacy
XPRIZE Healthspan is evaluating twenty finalist therapeutics across diverse modalities—stem cell therapies, genetic interventions, mitochondrial approaches, and others—using standardized measures of muscle, cognitive, and immune function. The competition explicitly judges interventions not only on biological efficacy but on manufacturing feasibility, cost structure, and realistic scalability, recognizing that population-level impact depends on more than laboratory performance.
Longevity capital pauses to think at Davos
The longevity field is maturing from speculative narrative to operational infrastructure, with investors and policymakers converging on evidence-based translation rather than technological spectacle. The shift reflects recognition that sustainable healthspan gains require business models and regulatory frameworks designed for decades-long compounding, not short-term capital cycles.
Longitudinal Biomarkers: From Snapshots to Clinical Trajectories
Continuous biomarker monitoring through at-home diagnostics—rather than annual snapshots—reveals whether health parameters are drifting toward dysfunction over months or years. This shift from episodic testing to longitudinal data collection addresses a critical gap in preventive medicine: understanding trajectories of biological change, not isolated readings.
Are global brands and employers longevity-ready?
Organizations across sectors remain structurally unprepared for demographic longevity, with the over-50 population underserved despite controlling significant spending power and representing a $67 billion market opportunity by 2035. Strategic repositioning toward healthspan optimization—rather than youth-centric models—is becoming a competitive and commercial imperative.
Longevity market projected to hit $67 billion by 2035
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by increased prevalence of age-related disease, adoption of preventive healthcare, and advances in regenerative medicine, genomics, and biomarker technologies. This expansion reflects a structural shift toward intervention before disease manifests.
Summer Consistency Programs Strengthen Wellness Adherence
Restore Hyper Wellness launched a summer challenge designed to reinforce consistent engagement with wellness services across its 200-studio network. The program incentivizes behavioral consistency through frequency-based rewards, addressing a known barrier to sustained health optimization: the difficulty of maintaining practice adherence during seasonal disruption.
Gut Microbiome Testing Paired With Unproven Longevity Compounds
Decode Age, a Bengaluru-based sequencing laboratory and supplement company, combines gut microbiome testing with the sale of compounds including NMN, resveratrol, spermidine, and alpha-ketoglutarate, marketed as bioage interventions. The startup has grown to ₹11.9 crore in annual revenue with recent institutional funding, though human efficacy data for these compounds remains limited.